Presynaptic Regulation of Dopamine Transmission in Schizophrenia

Gholson J. Lyon2,8, Anissa Abi-Dargham2,5, Holly Moore2,6, Jeffrey A. Lieberman2,7, Jonathan A. Javitch2,4,7,9, and David Sulzer1–4,9

2Department of Psychiatry; 3Department of Neurology; 4Department of Pharmacology, Columbia University, New York, NY; 5Division of Translational Imaging; 6Division of Integrative Neuroscience; 7Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, NY; 8Present address: Department of Child and Adolescent Psychiatry, NYU Child Study Center, New York, NY; 9These authors contributed equally to this work

A role for dopamine (DA) release in the hallucinations and other positive symptoms associated with schizophrenia has long been inferred from the antipsychotic response to D2 DA receptor antagonists and because the DA releaser amphetamine can be psychotogenic. Recent studies suggest that patients with schizophrenia, including those never exposed to antipsychotic drugs, maintain high presynaptic DA accumulation in the striatum. New laboratory approaches are elucidating mechanisms that control the level of presynaptic DA stores, thus contributing to fundamental understanding of the basic pathophysiologic mechanism in schizophrenia.

Key words: dopamine/positron emission tomography/vesicular monoamine transporter/aromatic amine decarboxylase/raclopride/F-DOPA/animal models/schizophrenia

Introduction

Approximately 1% of humanity develops schizophrenia during early adulthood, but the causes of this devastating disorder remain unknown. Over 20 susceptibility genes have been suggested to play a role,1,2 and environmental and/or epigenetic factors are also important, as evident from the approximately 50% discordance for schizophrenia between identical twins.3,4 Prenatal conditions, including malnutrition, maternal immune activation, and paternal age, may also provide susceptibility factors.2

Evidence of dopamine (DA) involvement in schizophrenia developed in tandem with the discovery of this neurotransmitter in the 1950s. Reserpine, from the plant Rauwolfia serpentina that has been used to treat insanity for centuries in India, was approved for antipsychotic use in the West in 1954 and was soon discovered to block the accumulation of DA and other catecholamines into adrenal chromaffin secretory vesicles.5 Carlsson6 speculated nearly 50 years ago that an imbalance in DA release might underlie psychosis.

Carlsson’s suggestion was buttressed when the clinical potencies of chlorpromazine, the first antipsychotic drug used in the West, and other “first-generation” antipsychotic drugs in the 1950s and 1960s were found to correlate with their binding affinities for D2-type DA receptors.7,8 Clinical response to most antipsychotics requires a minimum of 50% occupancy of striatal D2 receptors.9,10 While effective “second-” and “third-generation” antipsychotic drugs have been developed,11 the relationship between antipsychotic potency and D2 receptor affinity has been sustained.12–14 and the recent clinical antipsychotic trials of intervention effectiveness (CATIE) trial detected little difference between an older typical first-generation antipsychotic, perphenazine, and newer generation drugs.15

Additional support for a role of DA in schizophrenia arrived from the effects of psychostimulant drugs, including reports of widespread psychosis in populations in which amphetamines were widely abused, such as post–World War II Japan and Sweden in the 1940s and 1950s.16,17 Amphetamines release massive amounts of DA from presynaptic terminals, far more than with synaptic activity, and do so through mechanisms independent of synaptic vesicle exocytosis.18 Repeated amphetamine or methamphetamine use by individuals without schizophrenia can lead to a state similar to schizophrenic psychosis, with a propensity for psychotic reaction to subsequent psychostimulant exposure decades after the initial use.19 Premorbid schizoid or schizotypal personality predisposes methamphetamine users to psychosis, and the greater the personality vulnerability, the longer the psychosis persists.20 Many patients with schizophrenia exhibit an emergence or worsening of psychotic symptoms after acute exposure to amphetamine at doses that do not induce psychosis in healthy subjects.21 The patients who exhibit a worsening of psychotic symptoms in response to psychostimulant challenge during acute episodes are more likely to relapse upon antipsychotic discontinuation.22 Thus, both chronic and
Mechanisms underlying amphetamine sensitization, in which previous amphetamine exposure increases striatal DA release upon readministration,23 have been proposed to be relevant to psychosis.24 Amphetamine sensitization may be persistent; in humans, enhancement of amphetamine-evoked striatal DA efflux persists for at least 1 year following as few as 3 doses 48 hours apart.25 Patients with schizophrenia have been proposed to exhibit an “endogenous sensitization” in which repeated psychotic episodes show progressively higher elevations of presynaptic striatal DA26,27 that contribute to the progressively poorer clinical response to antipsychotic medications after each psychotic episode.28

Recent Evidence for Enhanced DA Accumulation

Amphetamine Displacement of D2 Receptor Occupancy

Much of the newer evidence for increased striatal DA levels in schizophrenia is from studies of D2 receptor occupancy in patients. DA receptors are found in nearly every class of neuron in the striatum. D2 autoreceptors are located on striatal DAergic axonal terminals, where they mediate negative feedback by inhibiting DA synthesis and release.29,30 On γ-aminobutyric acid–mediated (GABAergic) medium spiny neurons (MSNs), D2 receptors are highly expressed on neurons within the “indirect” striatopallidal pathway,31,32 particularly on dendritic spines proximal to the appositions or synapses formed by DA terminals.33 A presence of D2 receptors on the axons of some of the glutamatergic afferents from the cortex is supported by anatomical and electrophysiological studies.34–37 DA D1 and D2 receptors are also found on cholinergic and GABAergic interneurons of the striatum.38 Imaging findings of altered D2 receptor binding in striatum could reflect changes in any or all of these striatal D2 receptor populations.

The displacement of a radiolabeled D2/D3 ligand (iodobenzamide [IBZM], raclopride, or fallypride) in response to amphetamine can be used as an index of amphetamine-induced DA efflux in the striatum.38–40 Studies using this approach have shown that amphetamine-induced DA efflux is abnormally high in patients at the onset of psychosis, prior to treatment with antipsychotic drugs.38,41–43 A meta-analysis of imaging studies comparing D2 receptor parameters in patients with schizophrenia and healthy controls44 also revealed a small (12%) but significant elevation of striatal DA receptors in untreated patients with schizophrenia (see table 1). It is unclear what effect, if any, that this receptor elevation has in regard to the symptomatology in schizophrenia. However, because amphetamine causes substantial DA release through stimulation-independent nonexocytic mechanisms, these results indicate that there are higher-than-normal presynaptic levels of DA in the striatum of schizophrenic patients.

L-3,4-Dihydroxyphenylalanine Accumulation Studies

Presynaptic DA accumulation can be estimated in an alternate manner independent of D2 receptor binding from the accumulation of [18F] or [11C]-labeled 3,4-dihydroxyphenylalanine (DOPA).57–59 L-DOPA is rapidly converted to DA and [18F]DOPA to [18F]fluorodopamine in the cytosol by aromatic acid decarboxylase (AADC), and as nearly all the cytosolic DA in DA neurons is accumulated into synaptic vesicles,60 this approach mostly estimates presynaptic vesicular DA stores. Six of 8 studies report increased accumulation of [18F]DOPA or [11C]DOPA in the striatum of patients with schizophrenia (table 1).45,46,48–52 Consistent with the studies of amphetamine-induced DA release in antipsychotic-naive patients, 3 studies found increased striatal uptake of [18F]DOPA or [11C]DOPA in antipsychotic-naive subjects with schizophrenia compared with healthy control subjects (table 1).46,48,49 These data are consistent with the studies of amphetamine-induced displacement of DA D2 receptor radioligands as both indicate that there are increased levels of striatal presynaptic DA stores in patients with schizophrenia. It has also been shown that there is nearly 2-fold increased [18F]fluorodopamine turnover in the brains of untreated patients with schizophrenia, which is the largest biochemical difference yet reported.61 Interestingly, the 3 catatonic subjects tested in these studies46,47,49 possessed [18F]DOPA accumulation rates that were by far the lowest of any of the schizophrenic subjects and were also lower than controls, with [18F]DOPA accumulation rates comparable in magnitude to those measured in the putamen in Parkinson disease.62 This is consistent with a number of parallel features in the catatonic syndrome and neurological extrapyramidal disorders. While the [18F]DOPA findings suggest that the catatonic subtype of schizophrenia might be associated with abnormally low levels of DA, this is only based on studies in 3 subjects, and more patients need to be studied to substantiate this finding.

DA Depletion Studies

The amphetamine-D2 occupancy and L-DOPA imaging experiments indicate higher levels of presynaptic accumulation of DA in patients but do not indicate if there are higher levels of DA receptor occupancy in the patients. This question has been addressed by depleting DA with the tyrosine hydroxylase inhibitor, α-methyl-p-tyrosine (α-MPT), for 2 days to “unmask” D2 receptors that would otherwise be occupied by endogenous DA and would be unavailable to the labeled D2 ligand.27,39 The difference in binding between a DA-depleted and -nondepleted patient should indicate the D2 receptors that were bound by DA.

109
Following DA depletion, $[^{123}I]IBZM$ binding to D2 receptors was higher in patients with schizophrenia than in healthy controls. Within patients with schizophrenia, binding was higher for those experiencing an exacerbation of illness than for those who were not experiencing a psychotic episode. Assuming that the number and affinity of D2 receptors for DA are similar during and between psychotic episodes and that DA depletion does not alter D2 affinity (2 critical caveats), a higher fraction of striatal D2 receptors was apparently occupied by DA in patients with schizophrenia and the levels of DA correlated with the severity of psychosis. Higher synaptic DA levels in patients with schizophrenia were associated with the disease does not seem to be due to antipsychotic treatment. The important related question of whether DA neuronal activity, ie, the firing rate, is higher in patients with schizophrenia at baseline or during acute psychotic exacerbations has not been resolved (see below), and this could fundamentally alter the interpretation of these studies. It may be that the relatively long time windows measured by these imaging techniques reflect turnover of DA, so that at any given time, presynaptic levels are normal, but that there is a greater opportunity during the measurements for l-DOPA accumulation or amphetamine displacement of vesicle stores from the terminals that are more actively accumulating DA.

**Summary of Imaging Studies**

The results with labeled l-DOPA and amphetamine displacement of D2 ligands independently indicate that more DA is present in presynaptic terminals in the striatum of many patients with schizophrenia, with the possible exception of those with the catatonic subtype. The $\alpha$-MPT studies further indicate that baseline levels of striatal DA in patients are higher. Importantly, increased striatal DA associated with the disease does not seem to be due to antipsychotic treatment.

### Table 1. Imaging Studies of Striatal Presynaptic DA Parameters in Drug-Naive and Drug-Free Patients with Schizophrenia

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Study</th>
<th>Number of Controls</th>
<th>Number of Patients (DN/DF/T)</th>
<th>Radiotracer/Challenge</th>
<th>$P$</th>
<th>Effect Size$^b$</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOPA accumulation</td>
<td>Reith et al$^{35}$</td>
<td>13</td>
<td>5 (4/0/1)</td>
<td>$[^{18}F]$DOPA</td>
<td>&lt;.05</td>
<td>0.91</td>
</tr>
<tr>
<td></td>
<td>Hietala et al$^{46}$</td>
<td>7</td>
<td>7 (7/0/0)</td>
<td>$[^{18}F]$DOPA</td>
<td>&lt;.05</td>
<td>1.54</td>
</tr>
<tr>
<td></td>
<td>Dao-Castellana et al$^{47}$</td>
<td>7</td>
<td>6 (2/4/0)</td>
<td>$[^{18}F]$DOPA</td>
<td>ns</td>
<td>0.30</td>
</tr>
<tr>
<td></td>
<td>Lindstrom et al$^{48}$</td>
<td>10</td>
<td>12 (10/2)</td>
<td>$[^{11}C]$DOPA</td>
<td>&lt;.05</td>
<td>0.77</td>
</tr>
<tr>
<td></td>
<td>Hietala et al$^{49}$</td>
<td>13</td>
<td>10 (10/0)</td>
<td>$[^{18}F]$DOPA</td>
<td>&lt;.05</td>
<td>1.09</td>
</tr>
<tr>
<td></td>
<td>Elkashef et al$^{50}$</td>
<td>13</td>
<td>19 (9/9/9)</td>
<td>$[^{18}F]$DOPA</td>
<td>&lt;.05</td>
<td>0.65</td>
</tr>
<tr>
<td></td>
<td>Meyer-Lindenberg et al$^{51}$</td>
<td>6</td>
<td>6 (6/0/6)</td>
<td>$[^{18}F]$DOPA</td>
<td>&lt;.02</td>
<td>1.96</td>
</tr>
<tr>
<td></td>
<td>McGowan et al$^{52}$</td>
<td>12</td>
<td>16 (0/10/6)</td>
<td>$[^{18}F]$DOPA</td>
<td>&lt;.001</td>
<td>1.6</td>
</tr>
<tr>
<td></td>
<td>Howes et al$^{53}$</td>
<td>12</td>
<td>31 (27/4/0)$^c$</td>
<td>$[^{18}F]$DOPA</td>
<td>&lt;.05</td>
<td>0.78/1.24</td>
</tr>
<tr>
<td>Amphetamine-induced DA release</td>
<td>Laruelle et al$^{41}$</td>
<td>15</td>
<td>15 (2/13/0)</td>
<td>$[^{123}I]$IBZM/amphetamine</td>
<td>&lt;.05</td>
<td>1.51</td>
</tr>
<tr>
<td></td>
<td>Breier et al$^{58}$</td>
<td>18</td>
<td>18 (8/10/0)</td>
<td>$[^{11}C]$Raclopride/amphetamine</td>
<td>&lt;.05</td>
<td>1.73</td>
</tr>
<tr>
<td>Baseline DA concentration</td>
<td>Abi-Dargham et al$^{52}$</td>
<td>16</td>
<td>21 (1/20/0)</td>
<td>$[^{123}I]$IBZM/amphetamine</td>
<td>&lt;.05</td>
<td>1.07</td>
</tr>
<tr>
<td></td>
<td>Abi-Dargham$^{54}$</td>
<td>18</td>
<td>18 (8/10/0)</td>
<td>$[^{123}I]$IBZM/$\alpha$-MPT</td>
<td>&lt;.05</td>
<td>1.43</td>
</tr>
<tr>
<td></td>
<td>Kegeles et al submittedd</td>
<td>18</td>
<td>18 (6/12/0)</td>
<td>$[^{11}C]$Raclopride/$\alpha$-MPT</td>
<td>&lt;.05</td>
<td>in pre-DCA$^c$</td>
</tr>
<tr>
<td>DAT density</td>
<td>Laasko et al$^{55}$</td>
<td>9</td>
<td>9 (9/0/0)</td>
<td>$[^{13}F]$CFT</td>
<td>&lt;.05</td>
<td>0.11</td>
</tr>
<tr>
<td></td>
<td>Laruelle$^{67}$</td>
<td>22</td>
<td>22 (2/20/0)</td>
<td>$[^{123}I]$CIT</td>
<td>&lt;.05</td>
<td>0.43</td>
</tr>
<tr>
<td></td>
<td>Hsiao et al 2003$^{123}$</td>
<td>12</td>
<td>12 (12/0/0)</td>
<td>$[^{99mTc}]$TRODAT</td>
<td>ns</td>
<td>0.22</td>
</tr>
</tbody>
</table>

**Note:** Adapted from Int Rev Neurobiol 2007;78:17–20. $^{56}$ DA = dopamine; DOPA = 3,4-dihydroxyphenylalanine; IBZM = iodobenzamide; $\alpha$-MPT = $\alpha$-methyl-p-tyrosine; DAT = dopamine uptake transporter; ns = nonsignificant; dopamine transporter (DAT) ligand, $99m$TcTRODAT-1; $^{18}$F-radiolabelling synthesis ($^{18}$F; $T(1/2) = 109.8$ min) of 2-beta-carbomethoxy-3 beta-(4-fluorophenyl)tropane (also known as CFT or WIN 35,428); ligand $[^{123}I]2$ beta-carbomethoxy-3 beta-(4-iodophenyl)tropane (l$[^{123}I]$beta-CIT).

$^{a}$DN = drug naive; DF = drug free; T = treated with antipsychotics.

$^{b}$Effect size calculated as (mean patients – mean controls)/SD controls.

$^{c}$Twenty-four patients were considered “prodromal” or “at-risk mental state” (effect size 0.78) and 7 were new-onset psychotic patients (effect size 1.24).

$^{d}$This study is under submission, and results are reported by personal communication with permission of the first author.

$^{e}$pre-DCA = Precommissural dorsal caudate.
discussed below, the phenomena of enhanced striatal DA and low cortical DA could be related.

As increased presynaptic DA accumulation in the striatum in schizophrenia occurs independently of antipsychotic administration, it is possible that labeled L-DOPA could be used as a biomarker to identify disease progression or at-risk individuals. During the prodromal period, individuals exhibit symptoms of depression or “negative symptoms” of schizophrenia and sometimes subthreshold levels of positive symptoms. A recent [18F]DOPA imaging study of prodromal patients compared controls, “at-risk mental state” (ARMS) prodromal patients, and new-onset psychotic patients (table 1). This study replicated prior results within new-onset psychoses, showing that the psychotic patients had elevated [18F]DOPA in relation to controls. In addition, elevation of [18F]DOPA in the striatum (specifically the associative striatum) of 24 ARMS patients was significantly higher than controls. [18F]DOPA uptake was correlated with total prodromal symptom ratings and Positive and Negative Syndrome Scale score but was not correlated with depression or anxiety scores. Future imaging of these prodromal patients might provide insight concerning the “state- or trait-like” characteristics of DA accumulation in schizophrenia.

Fig. 1. Depiction of Presynaptic Mechanisms That Could Alter Dopamine (DA) Release. The availability of cytosolic DA for synaptic vesicle accumulation is regulated by conversion of tyrosine to 3,4-dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase (TH) followed by DA synthesized via aromatic acid decarboxylase (AADC). TH can be inhibited by α-methyl-p-tyrosine (not shown). Cytosolic DA is further regulated by reuptake of extracellular DA by the dopamine uptake transporter (DAT), which is driven by transmembrane sodium and chloride gradients (not shown); cytosolic DA is metabolized by mitochondrial monoamine oxidase (MAO) and aldehyde dehydrogenase (AD) and, after release, by extracellular DA metabolism by catechol-O-methyltransferase (COMT), which with extraneuronal MAO and AD, produces homovanillic acid (HVA). Under normal conditions, the great majority of cytosolic DA in presynaptic terminals is packaged into synaptic vesicles, which relies on the activity of an ATP-dependent vesicular proton pump (H+-ATPase) using ATP formed during oxidative phosphorylation (Ox Phos) at local mitochondria as well as local glucose uptake (not shown). The resulting transvesicular pH gradient is used to provide energy for DA accumulation by the vesicular monoamine transporter (VMAT) type 2. VMATs are inhibited by the ligands reserpine and tetrabenazine (TBZ) (not shown). Synaptic vesicle–mediated DA release is stimulated by cell body activity, which is driven by tonic activity and bursts driven by synaptic inputs and subject to regulation by receptors and myriad second messenger systems in dendrites and the cell body and conduction through the axon (not shown). The secretory response at the neuronal terminal is regulated by the D2 DA autoreceptor and heterosynaptic receptors, including metabotropic glutamate (mGluR1), nicotinic and muscarinic acetylcholine (nACHr and mAChr), GABA-A and -B, and kappa opioid receptors (not shown), and their effects on second messenger systems that regulate many steps in this scheme (large arrows), prominently including ion conductances via voltage-gated Ca++ channels that affect how synaptic vesicles are trafficked, docked, primed for fusion, fuse, and recycle. Also shown are steps involved in experimental approaches that suggest that DA release may be exacerbated in schizophrenia. Amphetamine (AMPH), which elicits DA release to displace D2 DA receptor ligands, increases extracellular DA via a combination of actions including redistribution of vesicular DA to the cytosol (not shown), reuptake blockade at the DAT (not shown), and reverse transport at the DAT. Extracellular L-DOPA or a labeled analog is accumulated via an amino acid transporter (AAT) and converted to DA or its labeled analog by AADC.
DA transporter expression is quite low.\textsuperscript{70–72} There are 2 major allele types for this enzyme at amino acid 158. When exposed to amphetamine, individuals without schizophrenia who exhibit the common Met/Met COMT genotype, which leads to slower DA metabolism than seen with the Val/Val form,\textsuperscript{73} exhibit poorer performance on high task-load tests than do those with the Val/Val form.\textsuperscript{73} A clinical analysis of the polymorphism in Japanese patients who take methamphetamine found that the Met allele is associated with patients who experienced methamphetamine psychosis and spontaneous relapse, suggesting that patients with 1 or 2 met alleles appear to be at increased risk of an adverse response to methamphetamine.\textsuperscript{74}

Evidence From the Laboratory for Altered Striatal DA

As discussed above, evidence in patients indicates that altered DA release in schizophrenia may be due to either intrinsic changes in the presynaptic terminal or changes in neuronal activity regulated by inputs from other neurons, particularly via altered cortical and subcortical or limbic regulation.

Presynaptic Studies

What underlies the increased presynaptic DA in patients with schizophrenia? Over the past decade, several new manipulations have been shown to alter presynaptic DA accumulation, including changes in DA synthesis, metabolism, and a variety of effects on quantal size (figure 1).

One possibility is that there is a higher density of DA terminals in the striatum of patients with schizophrenia. This is however inconsistent with reports of a normal density of DAergic mesostriatal neuronal terminals in the striatum of patients, using tyrosine hydroxylase immunocytochemistry.\textsuperscript{75–78}

Another possibility, that patients have increased DA synthesis due to higher activity of tyrosine hydroxylase (generally the rate-limiting step for DA synthesis), does not explain the phenomenon because imaging studies show enhanced accumulation of exogenous L-DOPA, the tyrosine hydroxylase product.

Enhanced DA uptake transport into neurons likewise does not appear to play a role, as postmortem studies consistently report unaltered dopamine transporter (DAT) levels in the striatum of patients with schizophrenia.\textsuperscript{75–78} Four of 5 in vivo imaging studies report normal striatal DAT density in young and/or antipsychotic-naive or -treated patients with schizophrenia.\textsuperscript{27,55,79,80}

There is likewise no evidence for enhanced expression of DA synaptic vesicle uptake transporters, although this has not been widely examined: One study finds normal vesicular monoamine transporter (VMAT) type 2 levels in patients using radiolabeled tetrabenazine as a ligand.\textsuperscript{81} Vesicular transporter activity has however not been assessed directly in patients.

An increased packaging of DA within synaptic vesicles might be the culprit. Amperometric recordings indicate that within the DA presynaptic terminal of cultured ventral midbrain DA neurons, the vast majority of DA is stored within the synaptic vesicles, which can maintain a concentration of nearly a molar.\textsuperscript{82} A new technique known as intracellular patch electrochemistry demonstrates that in contrast, the DA cell body cytosol normally contains <100 nM DA, although levels of 10 \(\mu\)M and higher can be reached in cytosol following L-DOPA.\textsuperscript{122}

Amperometric recordings from cultured neurons further show that the amount of DA stored within a synaptic vesicle can be regulated by a variety of relevant means, including altered cytosolic DA levels (as occurs when L-DOPA is administered), altered VMAT as mentioned above, altered vesicular pH gradients (which occurs with amphetamine), or changes in synaptic vesicle size.\textsuperscript{83,84} The demonstration of these modulatory mechanisms indicates that they might contribute to increased presynaptic DA accumulation in the disease state and almost certainly modify presynaptic DA accumulation under conditions such as when amphetamine is ingested.

Additional possibilities for enhanced presynaptic DA are suggested by the enhanced labeled L-DOPA accumulation observed in the disease. The rate of accumulation of [\(^{18}\)F]DOPA in the striatum depends on multiple factors, including transport through the blood-brain barrier, transport into cells by a possible L-amino acid transporter,\textsuperscript{85} and the activity of AADC that converts L-DOPA into DA. Once converted into DA, the synaptic vesicular storage capacity is important, as is the number of uptake-competent synaptic vesicles within a terminal. Importantly, intracellular patch electrochemistry measurements in DA neuronal culture suggests that the rate-limiting step for L-DOPA–derived DA accumulation likely occurs at AADC, with important additional effects on resulting cytosolic DA due to monoamine oxidase metabolism.\textsuperscript{122} To our knowledge, AADC activity has not been directly assessed in schizophrenia.

Studies of amphetamine sensitization may also provide important clues. Amphetamine-sensitized rats show greater amphetamine-induced displacement of striatal \(^{[3H]}\)raclopride\textsuperscript{86} and so may participate in the same mechanism that leads to high DA accumulation. Experiments on chromaffin cells indicate that prolonged methamphetamine increases the amount of catecholamine stored in vesicles via a rebound hyperacidification of vesicle pH gradients.\textsuperscript{122} Amphetamine can also stimulate DA synthesis, which contributes to some of its effects on DA release.\textsuperscript{18}

Cortical and Limbic Regulation Studies

Could altered limbic or cortical activity associated with schizophrenia\textsuperscript{87} underlie increased striatal presynaptic...
DA? In rodents, the frontal cortex can drive DA neuronal activity, but this drive may be much smaller in primates, who have little direct cortical input. Even in primates, however, the cortical activity modulates DA neuronal activity via cortical-basal ganglia loops, as nearly all cortical areas topographically project to the striatum and drive MSN activity, which in turn modulate the substantia nigra reticulata. Perhaps, this would promote greater DA neuronal activity and enhance DA turnover in the synaptic terminals.

Integrating the effects of all this regulation is complex, however. Within the striatum, ipsilateral motor area corticostriatal terminals are selected presynaptically, so that weaker inputs are inhibited by D2 DA receptors, possibly via a retrograde endocannabinoid signal from MSNs. Overall, it appears that ipsilateral cortical projection neurons project to D2-containing indirect pathway MSNs and show decreased activity with elevated DA release, as do tonically active cholinergic neurons in the striatum. In contrast, D1-containing direct pathway MSNs stimulated by both ipsilateral and contralateral projections show increased activity with DA release. Classic “box-and-arrow” models of the basal ganglia suggest that striatal DA release acting at both pathways might inhibit ventral midbrain GABA interneurons that disinhibit DA cell bodies and increase DA neuronal activity. Such a model is attractive, as it could explain how acute amphetamine challenge could maintain stimulation-dependent DA release and enhanced l-DOPA accumulation.

However, the disinhibition of DA neurons might be cancelled because high cortical activity can exert a long-lasting inhibition of striatal DA release by activating an inhibitory metabotropic glutamate type I presynaptic heteroreceptor. Cortical potentiation of acetylcholine released from tonically active cholinergic striatal neurons may enhance DA release via presynaptic nicotinic receptors on DA terminals, although its consequences on presynaptic DA stores are unknown. It is possible that corticostriatal homeostasis is altered by chronically elevated DA, as DA regulates the response of striatal and corticostriatal neurons via a variety of long-term changes of receptor and channel activity, including a very long-lasting depression of corticostriatal activity after repeated methamphetamine.

An alternate possibility to greater DA neuronal activity via reduced cortical “drive” is greater activity due to enhanced hippocampal output. Activation of the ventral hippocampus increases the firing of ventral tegmental neurons and enhances DA release in rodents. The effect on the nucleus accumbens may alter DA neuronal activity via a variation of the “box-and-arrow” basal ganglia model. It is not clear if either the altered cortical or limbic drive can explain the extent and characteristics of changes in presynaptic DA accumulation found in the imaging studies.

To provide even more complications, the decreased cortical or increased limbic input suspected to alter striatal DA may itself be a result of changes in the basal ganglia. Ventral tegmental area DA neurons that project to the cortex exhibit very different properties than those that project to various striatal areas, including low levels of D2 autoreceptors and DATs, and effects on these different populations of DA neurons could affect corticostriatal and mesostriatal projections in complex ways. Transgenic mice overexpressing striatal DA D2 receptors show increased prefrontal cortical DA levels and decreased rates of DA turnover as a result of a developmental compensation.

**Animal Model Studies**

The complex relationship of cortical and basal ganglia systems with DA can be revealed further by studying animal models of the disease. Indeed, the concept that striatal DA dysregulation might follow abnormal limbic and cortical input in schizophrenia has been very influential in the development of animal models. Neonatal ventral hippocampal lesions (NVHLs) lead to postpubertal emergence of phenotypes relevant to schizophrenia, including increased responsivity to the behavioral effects of amphetamine. Importantly, the increased behavioral response to amphetamine does not emerge until after puberty, a developmental pattern that may have high construct validity for the onset of psychosis in schizophrenia. The regulation of striatal DA release in this model is complex, with an increase in amphetamine-evoked DA efflux in the nucleus accumbens core but an attenuation of DA efflux in the nucleus accumbens shell.

In the methyloxazomethanol acetate model (MAM), a DNA methylator is administered at E17, which damages the hippocampus, prefrontal cortex, and other brain regions. Similar to the NVHL model, abnormal response to amphetamine does not emerge until after puberty. Promisingly, the MAM E17 rats possess increased amphetamine-induced DA efflux in the medial and ventral striatum (H.M., unpublished results, 2004), and there is an increased rate of firing by ventral tegmental area DA neurons.

Lesioning DA terminals in adult prefrontal cortex with 6-hydroxydopamine enhances striatal DA transmission possibly via increased stress-induced DA turnover in the nucleus accumbens regulated by noradrenergic inputs to the prefrontal cortex. Thus, several animal models suggest that aberrant cortical or limbic input to the striatum might underlie increased striatal presynaptic DA.

The near future is likely to bring us additional animal models, including those that exhibit alterations of proteins encoded by genes that contribute to the development of schizophrenia, and newly developed electrophysiological and optical methods promise to be important.
for understanding the complex relationship between the neuronal pathways that may underlie psychosis in schizophrenia.

Conclusions

Classic investigations by Carlsson and others suggested that abnormal DA input is involved in the positive symptoms of schizophrenia, and recent imaging studies have now focused these observations to show evidence for increased presynaptic DA stores in the striatum, with the apparent exception of catatonic patients. As summarized in Figure 1, there are a multiple, likely interacting, mechanisms regulating accumulation of DA in the presynaptic terminal and its excess in schizophrenia. Many of these mechanisms are downstream of the decreases in prefrontal cortical activity and increases in temporolimbic cortical activity (and their respective effects on DA neuron spike activity) that are predominantly featured in current rodent models of the pathophysiology of schizophrenia. Thus, far more work needs to be done to characterize local, perisynaptic factors regulating presynaptic DA stores. The new resources for studying presynaptic DA accumulation and release119,120 and the continuing development of new animal models promise that future research could elucidate these mechanisms.

Funding

National Institutes of Health; Picower and Parkinson’s Disease Foundations (DA07418 to D.S.); Lieber Center for Schizophrenia Research and Treatment.

Acknowledgments

We thank Andrew Dwork, Eleanor Simpson, and Christoph Kellendonk for helpful discussion and comments. The authors Javitch and Sulzer contributed equally to this work.

References


33. Sesack SR, Carr DB. Selective prefrontal cortex inputs to dopamine cells: implications for schizophrenia. Physiol Behav. 2002;77:513–517.

34. Wang H, Pickel VM. Dopamine D2 receptors are present in prefrontal cortical afferents and their targets in patches of the rat caudate-putamen nucleus. J Comp Neurol. 2002;442:392–404.


54. Abi-Dargham A, Rodenhiser J, Printz D, et al. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A. 2000;97:8104–8109.


111. Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA.
110. Corda MG, Piras G, Giorgi O. Neonatal ventral hippocampal 
lesions potentiate amphetamine-induced increments in 
dopamine efflux in the core, but not the shell, of the nucleus 

111. Moore H, Jentsch JD, Ghajarnia M, Geyer MA, Grace AA. 
A neurobehavioral systems analysis of adult rats exposed to 
methylazoxymethanol acetate on E17: implications for the 
neuropathology of schizophrenia. Biol Psychiatry. 2006;60: 
253–264.

112. Flagstad P, Mork A, Glenthoj BY, van Beek J, Michael-
Titus AT, Didrikson M. Disruption of neurogenesis on gesta-
tional day 17 in the rat causes behavioral changes relevant 
to positive and negative schizophrenia symptoms and alters 
amphetamine-induced dopamine release in nucleus accum-

113. Beyer CE, Steketee JD. Dopamine depletion in the medial 
prefrontal cortex induces sensitized-like behavioral and 
neurochemical responses to cocaine. Brain Res. 1999;833: 
133–141.

114. Pycock C, Kerwin R, Carter C. Effect of lesion of cortical 
dopamine terminals on subcortical dopamine receptors in 

115. Carlson JN, Visker KE, Keller RW, Jr, Glick SD. Left and 
right 6-hydroxydopamine lesions of the medial prefrontal 
cortex differentially alter subcortical dopamine utilization 
and the behavioral response to stress. Brain Res. 1996; 
711:1–9.

116. Bubser M. 6-Hydroxydopamine lesions of the medial pre-
frontal cortex of rats do not affect dopamine metabolism in 
the basal ganglia at short and long postsurgical intervals. 

117. King D, Zigmond MJ, Finlay JM. Effects of dopamine de-
pletion in the medial prefrontal cortex on the stress-induced 
increase in extracellular dopamine in the nucleus accumbens 

118. Venator DK, Lewis DA, Finlay JM. Effects of partial dopa-
ine loss in the medial prefrontal cortex on local baseline 
and stress-evoked extracellular dopamine concentrations. 

119. Heien ML, Wightman RM. Phasic dopamine signaling dur-
ing behavior, reward, and disease states. CNS Neurol Disord 

120. Schmitz Y, Benoit-Marand M, Gonon F, Sulzer D. Presynaptic 
2003;87:273–289.

121. Mosharov EV, Larsen KE, Phillips KA, et al. Interplay be-
tween cytosolic dopamine, calcium and alpha-synuclein 

122. Markov D, Mosharov EV, Setlik W, Gershon MD, Sulzer D. 
Secretory vesicle rebound hyperacidification and increased 
quanter size resulting from prolonged methamphetamine ex-

123. Hsiao MC, Lin KJ, Liu CY, Tzen KY, Yen TC. Dopamine 
transporter change in drug-naïve schizophrenia: an imaging 
study with 99mTc-TRODAT-1. Schizophr Res. 2003;65: 
39–46.